Gram-positive cocci infections in intensive care: Guide to antibacterial selection

Drugs

Volumn 66, Issue 6, 2006, Pages 751-768

  Álvarez Lerma, Francisco ^a,b   Grau, Santiago ^a   Gracia Arnillas, Maria Pilar ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; DALFOPRISTIN PLUS QUINUPRISTIN; FLUCONAZOLE; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL INFECTION; CATHETER INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; COST BENEFIT ANALYSIS; DRUG COST; ENTEROCOCCUS; GEOGRAPHICAL VARIATION (SPECIES); GRAM POSITIVE COCCI; HEALTH CARE POLICY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; MENINGITIS; MONOTHERAPY; MORTALITY; PNEUMONIA; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; MENINGITIS, BACTERIAL; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES; STAPHYLOCOCCAL INFECTIONS; URINARY TRACT INFECTIONS;

POSIBACTERIA;

EID: 33646816055     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666060-00003     Document Type: Review

References (121)

1. National Nosocomial Infection Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report: data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-85
2. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29: 245-52
3. Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis 1999; 33: 101-12
4. Valles J, Leon C, Alvarez-Lerma F, et al. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Clin Infect Dis 1997; 24: 387-95
5. Enright MC, Robinson DA, Randle G, et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A 2002; 99: 7687-92
6. CDC. Staphylococcus aureus resistant to vancomycin: United States 2002. MMWR 2002; 51: 565-7
7. Lynch JP, Zhanel GG. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin Respir Crit Care Med 2005; 26: 575-616
8. Baquero F, Garcia-Rodriguez JA, Garcia de Lomas J, et al. Spanish Surveillance Group for respiratory pathogens. Antimicrobial resistance of 1113 Streptococcus pneumoniae isolates from patients with respiratory infections in Spain: results of a 1 year (1996-1997) multicenter surveillance study: Antimicrob Agents Chemother 1999; 43: 357-9
9. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342: 710-21
10. Vandamme P, Vercauteren E, Lammens C, et al. Survey of enterococcal susceptibility patterns in Belgium. J Clin Microbiol 1996; 34: 2572-6
11. Rupp ME. Coagulase-negative staphylococcal infections: an update regarding recognition and management. Curr Clin Top Infect Dis 1997; 17: 51-87
12. Bartlett JG, Dowell SF, Mandell LA, et al. Guidelines for the management of community-acquired pneumonia. Clin Infect Dis 2000; 31: 347-82
13. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383-421
14. Fŕias J, Gomis M, Prieto J, et al. Tratamiento antibíotico empirico inicial de la neumonía adquirida en la comunidad. Rev Esp Quimioter 1998; 11: 255-61
15. Eguia JM, Chambers HF. Methicillin-resistant staphylococci and their treatment in the intensive care unit. Semin Respir Crit Care Med 2003; 24: 37-48
16. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infections Control Practices Advisory Committee (HICPAP). MMWR 1995; 44 (RR-12): 1-13
17. Garner JS. Guidelines for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17: 53-80
18. Clemett D, Markham A. Linezolid. Drugs 2000; 59 (4): 815-27
19. Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious Gram-positive infections. Drugs 1999; 58 (6): 1061-97
20. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-8
21. Dowzicky M, Talbot GH, Feger C, et al. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn Microbiol Infect Dis 2000; 37: 57-62
22. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-97
23. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388-94
24. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin sensitive episodes. Am J Respir Crit Care Med 1994; 150: 1545-9
25. Lepelletier D, Ferreol S, Villers D, et al. Methicillin-resistant Staphylococcus aureus nosocomial infections in ICU; risk factors, morbidity and cost. Pathol Biol (Paris) 2004; 52: 474-9
26. Álvarez-Lerma F, Palomar M, Insausti J, et al. Infecciones nosocomiales por Staphylococcus aureus en pacientes críticos en UCI. Med Clin (Barc) 2006. In press
27. Combes A, Trouillet JL, Joly-Guillou ML, et al. The impact of methicillin resistance on the outcome of poststernotomy mediastinitis due to Staphylococcus aureus. Clin Infect Dis 2004; 38: 822-9
28. Linden PK, Pasculle AW, Manez R, et al. Differences in outcome for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E faecium. Clin Infect Dis 1996; 22: 663-70
29. Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-87
30. Pauly DJ, Musa DM, Lestico MR, et al. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990; 10: 378-82
31. Jones ME, Draghi DC, Thornsberry C, et al. Emerging resistance among bacterial pathogens in the intensive care unit: a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004; 3: 14
32. Álvarez-Lerma F, Palomar M, Olaechea P, et al. Estudio nacional de vigilancia de infección en unidades de cuidados intensivos: informe del año 2001. Med Intensiva 2005; 29: 13-23
33. Marco E, Bouza E, García de Lomas J, et al. Streptococcus pneumoniae in community-acquired respiratory tract infections in Spain: the impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics. J Antimicrob Chemother 2000; 46: 557-64
34. Shortridge VD, Doern GV, Brueggemann AB, et al. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999; 29: 1186-8
35. Hanaki H, Yamaguchi Y, Yanagisawa C, et al. Investigation of beta-lactam-antibiotic-induced vancomycin-resistant MRSA (BIVR). J Chemother 2005; 11: 104-6
36. Baquero F. Pneumococcal resistance to beta-lactam antibiotics: a global geographic overwiew. Microb Drug Resist 1995; 1: 115-20
37. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother 2000; 46 Suppl. T1: 3-9
38. Nissinen A, Leinonen M, Huovinen P, et al. Antimicrobial resistance of Streptococcus pneumoniae in Finland, 1987-1990. Clin Infect Dis 1995; 20: 1275-80
39. Hermans PW, Sluijter M, Elzenaar K, et al. Penicillin-resistant Streptococcus pneumoniae in the Netherlands: results of a 1-year molecular epidemiologic survey. J Infect Dis 1997; 175: 1413-22
40. Doern GV, Brueggemann A, Holley HP, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center National Surveillance Study. Antimicrob Agent Chemother 1996; 40: 1208-13
41. Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in the 1996-1997 respiratory season: the TRUST study. Diagn Microbiol Infect Dis 1997; 29: 249-57
42. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74
43. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-8
44. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676-85
45. Alvarez-Lerma F. Modification of empiric treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22: 387-94
46. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-55
47. Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 224: 379-86
48. Zaragoza R, Artero A, Camarena JJ, et al. The influence of inadequate empirical antrimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003; 9: 412-8
49. Korzeniowski OM. Antimicrobial therapy of infective endocarditis and Korzeniowski OM. Cardiovascular infections. In: Mandell GL, editor. Volume X: atlas of infections diseases. Philadelphia: Churchill Livingston, 1998
50. Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalation strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122: 2183-96
51. Kollef M. Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs 2003; 63: 2157-68
52. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 32: 2183-219
53. Alvarez Lerma F, Alvarez B, Rello J, et al. Antibiotic de-escalation therapy (DT) for nosocomial pneumonia (NP) in ICU (ADANN study) [abstract no. 250]. 16th Annual Congress of the European Society of Intensive Care Medicine. Amsterdam. October 2003. Intensive Care Med 2003; 29 Suppl. 1: S68
54. Niederman MS, Mandell LA, Anzueto A, et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54
55. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33
56. American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416
57. Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia; risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160: 923-9
58. Smith MD, Derrington P, Evans R, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Stretococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003; 41: 2810-3
59. Gutierrez F, Masia M, Rodriguez JC, et al. Evaluation of the immunochromatogrphic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36: 286-92
60. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999; 159: 1835-42
61. File TM. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 34: S17-26
62. Pallares R, Liñares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-80
63. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis 2002; 34: 1613-20
64. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837-42
65. Rello J, Catalan M, Diaz E, et al. Association between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002; 28: 1030-5
66. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteriemic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389-95
67. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997; 337: 970-6
68. Viladrich PF, Cabellos C, Pallarés R, et al. High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1996; 40: 218-20
69. Fenoll A, Asensio G, Jado I, et al. Antimicrobial susceptibility and pneumococcal serotypes. J Antimicrob Chemother 2002; 50 Suppl. S2: 13-9
70. Catalan MJ, Fernandez JM, Vazquez A, et al. Failure of cefotaxime in the treatment of meningitis due relatively resistant Streptococcus pneumoniae. Clin Infect Dis 1994; 18: 766-9
71. Friedland IR, Paris M, Ehrett S, et al. Evaluation of antimicrobial regimens for treatment of experimental penicillin and cephalosporin resistant pneumococcal meningitis. Antimicrob Agent Chemother 1993; 37: 1630-6
72. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347: 1549-56
73. Jorda R, Torres A, Ariza JF, et al. Recomendaciones para el tratamiento de la neumonía intrahospitalaria grave. Med Intensiva 2004; 28: 262-78
74. Rello J, Ausina V, Castella J, et al. Nosocomial respiratory tract infections in multiple trauma patients: influence of level of consciousness with implications for therapy. Chest 1992; 102: 525-9
75. Langer M, Cigada M, Mandelli M, et al. Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Med 1987; 13: 342-6
76. Rello J, Ausina V, Ricart M, et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associted pneumonia. Chest 1993; 104: 1230-5
77. Alvarez-Lerma F, Palomar M, Martinez-Pellus A, et al. Aetiology and diagnostic techniques in intensive care-acquired pneumonia: a Spanish multi-centre study. Clin Intensive Care 1997; 8: 164-70
78. Conte E, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46: 1475-80
79. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37: 281-6
80. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Crit Care Med 2000; 161: 753-62
81. Kitzis MD, Ly A, Goldstein FW. In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2004; 48: 366-7
82. Hebeisen P, Heinze-Krauss I, Angehrn P, et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001; 45: 825-36
83. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149-52
84. Allen GP, Cha R, Rybak MJ. In vitro, activities of quinupristin- dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2002; 46: 2606-12
85. Aeschlimann JR, Allen GP, Hershberger E, et al. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob Agents Chemother 2000; 44: 2991-8
86. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290: 2588-98
87. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24: 584-602
88. Fidalgo S, Vazquez F, Mendoza MC, et al. Bacteremia due to Staphylococcus epidermidis: microbiologic, epidemiologic, clinical, and prognostic features. Rev Infect Dis 1990; 12: 520-8
89. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis 2005; 40: 374-80
90. Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 2005; 56: 337-43
91. Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001; 40: 833-86
92. Pea F, Porreca L, Baraldo M, et al. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000; 45: 329-35
93. Sádaba B, Azanza JR. Farmacocinética en situaciones especiales (geriatría, recién nacidos, y niños, embarazo y puerperio). In: Garcia Sanchéz JE, Lopez R, Prieto J, editors. Sociedad Española de Quimioterapia: antimicrobianos en medicina. Barcelona: Proas Science SA, 1999: 121-31
94. Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 2005; 55: 333-40
95. Blondeau JM, Hansen G, Metzler K, et al. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004; 16 Suppl. 3: 1-19
96. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 159-60
97. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81
98. Highet VS, Forrest A, Ballow CH, et al. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother 1999; 43 Suppl. A: 53-63
99. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 Suppl. 3: 38-44
100. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with development of bacteria resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-7
101. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17: 479-501
102. Moise PA, Forrest A, Bhavnani SM, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000; 57 Suppl. 2: S4-9
103. Rayner CR, Forrest A, Meagher AK, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-23
104. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42: S35-9
105. Slattery JT. A pharmacokinetic model-independent for estimating dose required to give derived steady-state trough concentrations of drug in plasma. J Pharmacokinet Biopharm 1993; 8: 105-10
106. Turner JV, Maddalena DJ, Cutler DJ, et al. Multiple pharmacokinetic parameter for a series of cephalosporins. J Pharm Sci 2003; 92: 552-9
107. Álvarez-Lerma F, Grau S, Marín-Casino M, et al. GEIPC-SEIMC. Monitorización de concentraciones plasmáticas de antibióticos en hospitales españoles. Enferm Infec Microbiol Clin 2005; 23: 533-9
108. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7
109. Blot S. MRSA pneumonia: better outcome through continuous infusion of vancomycin? Crit Care Med 2005; 33: 2127-8
110. Alvarez Lerma F, Gasulla Guillermo M, Abad Peruga V, et al. Identificación de los tiempos de riesgo de diseminación de Staphylococcus aureus resistente a meticilina (SARM) en una unidad de Medicina Intensiva. Med Clin (Barc) 2004; 123: 207-10
111. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36: 53-9
112. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36: 592-8
113. Pelz RK, Lipsett PA, Swoboda SM, et al. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Med 2002; 28: 692-7
114. Garrelts JC, Horst WD, Silkey B, et al. A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy 1994; 14: 438-45
115. Darko W, Medicis JJ, Smith A, et al. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 2003; 23: 643-50
116. Shah NP, Reddy P, Paladino JA, et al. Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus: an economic model. Curr Med Res Opin 2004; 20: 779-90
117. Janknegt R. The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic and pharmacoeconomic considerations. Pharm World Sci 1997; 19: 133-41
118. Abad F, Calbo F, Zapater P, et al. Comparative pharmacoeconomic study of vancomycin and teicoplanin in intensive care patients. Int J Antimicrob Agents 2000; 15: 65-71
119. Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004; 32: 137-43
120. Grau S, álvarez-Lerma F, Del Castillo A, et al. Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain. J Chemother 2005; 17: 203-11
121. Álvarez-Lerma F, Palomar M, Grau S. Management of antimicrobial use in the intensive care unit. Drugs 2001; 61: 763-75